Lista de obras - Udai Banerji - Dominio Público Uruguay

89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.

artículo científico publicado en 2014

A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.

artículo científico publicado en 2017

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

artículo científico publicado en 2018

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

artículo científico publicado en 2010

A genome-scale CRISPR screen identifies the ERBB and mTOR signalling networks as key determinants of response to PI3K inhibition in pancreatic cancer

artículo científico publicado en 2020

A multicenter study of recombinant interferon-alpha 2b in the treatment of multibacillary leprosy

artículo científico publicado en 1997

A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors

artículo científico publicado en 2013

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors

artículo científico publicado en 2012

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

artículo científico publicado en 2016

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

artículo científico publicado en 2013

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

artículo científico publicado en 2016

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

artículo científico publicado en 2010

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

artículo científico publicado en 2018

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

artículo científico publicado en 2017

A study of motivations and expectations of patients seen in phase 1 oncology clinics

scientific article published on 26 September 2016

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

artículo científico publicado en 2010

AKT Inhibition in Solid Tumors With AKT1 Mutations

artículo científico publicado en 2017

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

artículo científico publicado en 2014

Antibody-drug conjugates--an emerging class of cancer treatment

artículo científico publicado en 2016

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

artículo científico publicado en 2014

Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

artículo científico publicado en 2015

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.

artículo científico publicado en 2012

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

artículo científico publicado en 2008

Biomarkers in early clinical trials: the committed and the skeptics

scientific article published on 01 April 2008

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development

artículo científico publicado en 2016

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

artículo científico publicado en 2009

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

scientific article published on 20 April 2020

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

artículo científico publicado en 2016

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

artículo científico publicado en 2017

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

artículo científico publicado en 2009

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?

scientific article published on 26 March 2007

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

artículo científico publicado en 2017

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

artículo científico publicado en 2017

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials

scientific article published on 17 July 2018

Combinatorial drug therapy for cancer in the post-genomic era.

artículo científico publicado en 2012

Combine and conquer: challenges for targeted therapy combinations in early phase trials.

artículo científico publicado en 2016

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

artículo científico publicado en 2015

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models

scientific article published on 01 November 2018

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials ⬇️

artículo científico publicado el 7 de agosto de 2012

Critical parameters in targeted drug development: the pharmacological audit trail

artículo científico publicado en 2016

Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp

artículo científico publicado en 2019

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

artículo científico publicado en 2012

Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.

artículo científico publicado en 2017

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

scientific article published on 01 July 2019

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy

artículo científico publicado en 2012

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models

artículo científico publicado en 2017

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

scientific article published on 21 April 2020

Exploiting the folate receptor α in oncology

scientific article published on 09 March 2020

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

artículo científico publicado en 2015

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

artículo científico publicado en 2019

First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors

artículo científico publicado en 2013

First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors

artículo científico publicado en 2020

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

artículo científico publicado en 2014

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

artículo científico publicado en 2012

From darkness to light with biomarkers in early clinical trials of cancer drugs.

artículo científico publicado en 2009

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

artículo científico publicado en 2007

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

artículo científico publicado en 2000

Heat shock protein 90 as a drug target: some like it hot.

scientific article published on January 2009

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

artículo científico publicado en 2017

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

artículo científico publicado en 2015

Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management

artículo científico publicado en 2016

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

artículo científico publicado en 2017

Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600-Wild-Type Colorectal Cancer

artículo científico publicado en 2020

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer

artículo científico publicado en 2016

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

artículo científico publicado en 2003

Maximising the potential of AKT inhibitors as anti-cancer treatments

artículo científico publicado en 2016

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

artículo científico publicado en 2017

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

artículo científico publicado en 2012

Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services

scientific article published on 16 May 2019

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.

artículo científico publicado en 2017

Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials

artículo científico publicado en 2011

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with

artículo científico publicado en 2018

Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.

artículo científico publicado en 2015

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

artículo científico publicado en 2005

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

artículo científico publicado en 2017

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

artículo científico publicado en 2017

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

artículo científico publicado en 2005

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

artículo científico publicado en 2020

Phase I trial outcomes in older patients with advanced solid tumours

artículo científico publicado en 2016

Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit

artículo científico publicado en 2014

Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma

artículo científico publicado en 2000

Radiological patterns of drug induced interstitial lung disease (DILD) in early phase oncology clinical trials

artículo científico publicado en 2020

Revisiting the role of molecular targeted therapies in patients with brain metastases.

scientific article published on 22 July 2011

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

artículo científico publicado en 2018

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

artículo científico publicado en 2015

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre

scientific article published on 15 October 2018

Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions ⬇️

artículo científico publicado el 28 de noviembre de 2012

The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future ⬇️

artículo científico publicado el 1 de octubre de 2003

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

artículo científico publicado en 2012

The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer.

artículo científico publicado en 2006

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

artículo científico publicado en 2010

The kinase polypharmacology landscape of clinical PARP inhibitors

scientific article published on 17 February 2020

The off-target kinase landscape of clinical PARP inhibitors

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

artículo científico publicado en 2018

Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials ⬇️

artículo científico publicado el 1 de noviembre de 2012

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.

artículo científico publicado en 2015

Toward a better dialogue between neuro-oncologists and phase I investigators.

artículo científico publicado en 2012

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

artículo científico publicado en 2019

Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein Quantification

artículo científico publicado en 2017

Lista de obras de Udai Banerji

89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.

A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

A genome-scale CRISPR screen identifies the ERBB and mTOR signalling networks as key determinants of response to PI3K inhibition in pancreatic cancer

A multicenter study of recombinant interferon-alpha 2b in the treatment of multibacillary leprosy

A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

A study of motivations and expectations of patients seen in phase 1 oncology clinics

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

AKT Inhibition in Solid Tumors With AKT1 Mutations

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

Antibody-drug conjugates--an emerging class of cancer treatment

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Biomarkers in early clinical trials: the committed and the skeptics

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials

Combinatorial drug therapy for cancer in the post-genomic era.

Combine and conquer: challenges for targeted therapy combinations in early phase trials.

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials ⬇️

Critical parameters in targeted drug development: the pharmacological audit trail

Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

Exploiting the folate receptor α in oncology

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors

First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

From darkness to light with biomarkers in early clinical trials of cancer drugs.

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

Heat shock protein 90 as a drug target: some like it hot.

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600-Wild-Type Colorectal Cancer

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

Maximising the potential of AKT inhibitors as anti-cancer treatments

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.

Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with

Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

Phase I trial outcomes in older patients with advanced solid tumours